# MarketBeat.com

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/marketbeatcom
Canonical HTML page: https://getyourbrief.com/entity/marketbeatcom

## Timeline

- **2026-08-23**: Wall Street Zen upgrades both stocks to Hold — Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
- **2026-08-16**: Wall Street Zen upgrades both stocks — Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
- **2026-08-14**: Quarterly earnings release — Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
- **2026-08-14**: Friday trading close — AMPY opened at $4.78 and BRSP opened at $5.00.
- **2026-08-14**: Enveric reports quarterly loss — Enveric Biosciences reported EPS of -$0.76 for the quarter.
- **2026-08-13**: Q2 earnings released; EPS beats consensus — Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
- **2026-08-11**: Benchmark and Weiss update AMPY — Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
- **2026-08-08**: Wall Street Zen downgrades to Hold — Wall Street Zen cut both Klaviyo and Oceaneering International from Buy to Hold in Saturday research notes.
- **2026-08-07**: Citigroup lifts KVYO target — Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
- **2026-08-06**: KVYO analyst revisions — Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
- **2026-08-05**: Klaviyo Q2 earnings — Klaviyo reported EPS of $0.19, meeting consensus, and revenue of $370.58 million.
- **2026-07-31**: RBC raises CTNM target to $23 — Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
- **2026-07-30**: OII insider sale — SVP Christopher J. Dyer sold 1,200 OII shares at an average price of $47.65 for $57,180.
- **2026-07-30**: B. Riley trims BRSP target — B. Riley Financial lowered its BrightSpire Capital target from $7.00 to $6.50 with a buy rating.
- **2026-07-30**: Contineum reports Q2 results — Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.

## Recent coverage (18 stories, network-wide)

### Hold Upgrades for CTNM and ENVB: $20.25 Target vs $1.43 Microcap
2026-08-24 11:32:31 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
Full story: https://getfinancebrief.com/story/wall-street-zen-ctnm-envb-hold-upgrades-finance

### Wall Street Zen Upgrades 2 Biotechs: CTNM at $17.19, ENVB at $1.43
2026-08-24 11:32:21 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Full story: https://getbiobrief.com/story/wall-street-zen-upgrades-two-biotechs-ctnm-envb-hold-bio

### AMPY Upgraded to Hold: $4.78 Stock, $9 Target, 10.6 P/E
2026-08-18 04:52:49 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Full story: https://getfinancebrief.com/story/ampy-wall-street-zen-hold-upgrade-finance

### RTX Up 1.1% With $250 High Target; GEV Gains 1.3% as Analysts See $1,338
2026-08-17 03:06:46 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analysts remain mostly bullish on RTX and GE Vernova after July earnings, lifting price targets to as high as $250 and $1,338 respectively. Friday's gains came on unusually light volume, raising questions about conviction. Finance readers get a breakdown of target upside, valuation, and risk metrics.
Full story: https://getfinancebrief.com/story/rtx-gev-analyst-targets-low-volume-gains

### ZOOZ Power's 85% Upside vs Regal Rexnord's 39.6%: Which Wins?
2026-08-17 01:17:34 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A MarketBeat-based comparison shows ZOOZ Power offers 85.01% implied upside versus Regal Rexnord's 39.62%, but the ownership and volatility profiles point in opposite directions. Regal Rexnord wins on 9 of 12 factors, yet ZOOZ's insider-heavy ownership and analyst target suggest a higher-reward, lower-liquidity opportunity.
Full story: https://getfinancebrief.com/story/zooz-power-vs-regal-rexnord-upside-ownership

### MBRX Down 97% to $0.57 Despite EPS Beat: $22 Target Stale?
2026-08-17 00:56:51 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Full story: https://getfinancebrief.com/story/mbrx-down-97-percent-eps-beat-22-target-stale

### Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
2026-08-17 00:56:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Full story: https://getbiobrief.com/story/moleculin-4m-market-cap-eps-loss-pipeline-survival

### Lantern Pharma Misses EPS by $0.19; AI Oncology Stock Sits 44% Below High
2026-08-16 16:15:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Full story: https://gethealthbrief.com/story/lantern-pharma-eps-miss-health-ai-oncology

### LTRN Misses EPS by $0.19 Yet Rises 0.8% to $2.65 on 2.3x Volume
2026-08-16 16:14:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Full story: https://getfinancebrief.com/story/ltrn-q2-earnings-miss-stock-reaction

### Lantern Pharma Posts $0.57 Loss, Misses Consensus by $0.19; Sell Rating Stands
2026-08-16 16:14:45 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Full story: https://getbiobrief.com/story/lantern-pharma-clinical-stage-eps-miss

### Morgan Stanley Cuts AMH PT to $38, Sees 11% Upside in SFR
2026-08-16 15:04:23 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Single-family rental REIT American Homes 4 Rent has a modestly reduced $38 price target from Morgan Stanley, still above a $36.78 consensus and leaving 11% upside. The maintained Overweight rating reinforces the resilience of the SFR asset class amid housing supply constraints.
Full story: https://getproptechbrief.com/story/morgan-stanley-amh-38-proptech-sfr

### Morgan Stanley Cuts AMH PT to $38; Consensus $36.78, 11% Upside
2026-08-16 15:04:14 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Morgan Stanley trimmed its American Homes 4 Rent target to $38 from $38.50 while keeping an Overweight rating, against a $36.78 consensus and Moderate Buy average. Equity research actions from Jefferies, UBS, RBC, Mizuho, and Compass Point reveal a broadly constructive but price-sensitive stance on the REIT.
Full story: https://getfinancebrief.com/story/morgan-stanley-amh-price-target-38-finance

### SaaS Valuation Stress: Klaviyo's 896x P/E Draws Wall Street Zen Hold
2026-08-13 01:19:31 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 2

SaaS and cloud operators are watching Klaviyo as a high-multiple vertical SaaS proxy. Wall Street Zen's Buy-to-Hold cut, after Q2 revenue of $370.58 million and EPS in line, shows how quickly a premium valuation can compress when growth doesn't exceed expectations.
Full story: https://getsaasbrief.com/story/saas-klaviyo-wall-street-zen-hold-896-pe

### Klaviyo Hit with Hold at $17.91: 896 P/E Meets $370.6M Q2
2026-08-13 01:19:20 · Sector: marketing · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Marketing and AdTech teams relying on Klaviyo face new investor scrutiny after Wall Street Zen cut the stock to Hold despite Q2 revenue of $370.58 million and in-line EPS of $0.19. The downgrade lands as analyst targets diverge while the company trades at a 895.95 P/E, raising questions about martech spending sustainability.
Full story: https://getmarketingbrief.com/story/klaviyo-wall-street-zen-downgrade-896-pe

### Wall Street Zen Cuts OII and KVYO to Hold: $5B Caps, 14.6 vs 896 P/E
2026-08-13 01:19:06 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen downgraded both Oceaneering International and Klaviyo from Buy to Hold, spotlighting two $5 billion market-cap companies with vastly different P/E ratios—14.59 for OII and 895.95 for KVYO. The ratings actions come as consensus targets diverge from current prices.
Full story: https://getfinancebrief.com/story/finance-wall-street-zen-downgrade-oii-kvyo

### NexGel's 23.4% Insider Stake Tops Bluejay's 18.5% Institutions
2026-08-12 16:39:43 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

This review offers healthcare strategists a snapshot of two small-cap suppliers: NexGel's insider-heavy ownership and stronger profitability versus Bluejay's institutionally backed diagnostic platform.
Full story: https://gethealthbrief.com/story/nexgel-nxgl-bluejay-bjdx-healthcare-trend

### NexGel $2 Target Means 284.69% Upside Over Bluejay
2026-08-12 16:39:36 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A MarketBeat comparison finds NexGel beats Bluejay Diagnostics on 9 of 13 metrics, with a $2.00 target and 284.69% upside. The biotech lens highlights divergent risk profiles between a diagnostics platform and a biomaterials company.
Full story: https://getbiobrief.com/story/nexgel-nxgl-bluejay-bjdx-biotech-comparison

### Rivian Faces Mounting Pressure as Analysts Issue Dual Bearish Downgrades
2026-02-19 13:52:44 · Sector: climate · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Rivian Automotive is facing increased scrutiny as DA Davidson and Wall Street Zen both downgraded the EV maker's stock, citing valuation and performance risks. While Benchmark remains a bullish outlier, the consensus reflects growing caution regarding Rivian's path to profitability in a cooling market.
Full story: https://getclimatebrief.com/story/rivian-stock-downgrade-da-davidson-wall-street-zen

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.